Plasma EVs with EpCAM and CD44V6 also have a prognostic role in PDAC, with the former’s levels being associated with the treatment response during systemic, palliative chemotherapy in advanced PDAC cases, as well as with the tumor stage [210], whereas the latter’s are only related to the tumor stage [193]. This evidence concerns the gene EPCAM and neoplasm.